TON - September 2018, Vol 11, No 4

TON - SEPTEMBER 2018, Vol 11, No 4

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.
“Our study shows that medical marijuana is a salient topic in cancer care today, and the majority of oncologists think it may have utility for certain patients….however, data on medical marijuana use is less so,” said Ilana M. Braun, MD.
Chicago, IL—In the United States, black men are twice as likely to die from prostate cancer as white men, and they are often diagnosed at a younger age and at later stages of the disease.
Page 2 of 2
Results 11 - 14 of 14